Menu
Home / Guides / Semaglutide results timeline
Week by week. Month by month.
Semaglutide Results Timeline (2026): What to Expect, Week by Week
By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD (NPI 1144260043) · Updated
Semaglutide results are gradual: in Wegovy’s 68-week trial, people on 2.4 mg lost 14.9% of their weight on average, versus 2.4% on placebo. The label, read November 15, 2026, raises the dose over the first 16 weeks, from 0.25 mg; these trials studied FDA-approved Wegovy, and compounded semaglutide wasn’t studied.
- Results build over months: the trial measured them at week 68
- Your schedule: set by your provider, not by this page
- Averages: they describe a group, not you
What’s the semaglutide results timeline from week 1 to week 68?
- Weeks 1–4
- 0.25 mg, the starting dose
- Weeks 5–16
- A step up every 4 weeks: 0.5, 1, then 1.7 mg
- Week 17 on
- Maintenance: 1.7 or 2.4 mg
- Week 68
- Results measured in the main trial
- Compounded semaglutide
- Not studied in these trials
Questions about your progress? Call or text
Compounded medicines aren’t FDA-approved. A NexLife provider prescribes one only if it offers a significant difference for you compared with an FDA-approved medicine.
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- Semaglutide results build over months: in Wegovy’s 68-week trial, people on 2.4 mg lost 14.9% on average, versus 2.4% on placebo.
- The first 16 weeks are dose steps, from 0.25 mg; maintenance at 1.7 or 2.4 mg starts in week 17.
- Most reached 5%: 83.5% on 2.4 mg lost at least 5%, and 30.2% lost at least 20% (31.1% and 1.7% on placebo).
- Averages describe a group, not you. People with type 2 diabetes lost less, and weight came back in people who stopped.
- Compounded semaglutide wasn’t studied in these trials and isn’t FDA-approved. Your prescription sets your own steps.
- At NexLife, a licensed provider decides each step, at one price: $95 a month on the 12-month plan.
How long
How long does semaglutide take to work?
Weight comes off over months, not weeks. The Wegovy label (revised June 2026) raises the dose every 4 weeks and reaches maintenance in week 17. Its main trial measured results at week 68. These trials studied FDA-approved Wegovy; compounded semaglutide wasn’t studied. In your first weeks, you’re still on the label’s starting doses.
The label says semaglutide lowers how much you eat, likely by acting on appetite, and that the weight lost is more fat than lean mass. It also slows how fast your stomach empties.
The label starts at 0.25 mg and steps up every 4 weeks. In the main trial, doses rose to 2.4 mg over 16 weeks, followed by 52 weeks on that dose.
Another trial in the label, Study 5, gives an earlier point. In it, 803 people reached 2.4 mg during a 20-week lead-in. They averaged 107.2 kg at the start and 96.1 kg at week 20 (the label’s Table 9). The label warns this group may not reflect everyone starting out; compounded semaglutide wasn’t studied.
The main trial’s results, in the label’s Table 8: 14.9% of body weight lost on average on 2.4 mg, versus 2.4% on placebo. Compounded semaglutide wasn’t studied.
From the Wegovy prescribing information (revised June 2026), sections 12 and 14. These trials studied FDA-approved Wegovy; compounded semaglutide wasn’t studied.
Before and after
What does semaglutide before and after look like, month by month?
In the trials, it looked like gradual loss over more than a year. In STEP 1, a 68-week trial, people on 2.4 mg started at 105.4 kg on average and lost 14.9% of their weight, versus 2.4% on placebo; the trial’s paper puts it at 15.3 kg, versus 2.6 kg. These are trial averages for FDA-approved Wegovy, not a promise for you, and compounded semaglutide wasn’t studied.
| When | What the trials found |
|---|---|
| Month 1 (weeks 1–4) | 0.25 mg a week, the starting dose. |
| Months 2–4 (weeks 5–16) | A step up every 4 weeks: 0.5, 1, then 1.7 mg; maintenance at 1.7 or 2.4 mg starts in week 17. Stomach side effects were reported most often while the dose was going up. |
| About month 5 (week 20) | In Study 5, people who reached 2.4 mg in a 20-week lead-in averaged 107.2 kg at the start and 96.1 kg at week 20. |
| About month 16 (week 68) | In STEP 1, average loss was 14.9% on 2.4 mg, versus 2.4% on placebo. 83.5% lost at least 5%, and 30.2% lost at least 20%. |
Group averages from trials of FDA-approved Wegovy, from its prescribing information (revised June 2026). Months are approximate: a month is about 4.3 weeks. Compounded semaglutide wasn’t studied.
What changed besides the scale? In STEP 1, waist size, blood pressure, triglycerides and HbA1c fell more on semaglutide than on placebo, HDL (“good”) cholesterol rose, and heart rate went up slightly.
| Measure | Change on 2.4 mg | Change on placebo |
|---|---|---|
| Waist (114.6 cm at the start) | −13.5 cm | −4.1 cm |
| Systolic blood pressure (126 mmHg) | −6.2 mmHg | −1.1 mmHg |
| Diastolic blood pressure (80 mmHg) | −2.8 mmHg | −0.4 mmHg |
| Triglycerides | −21.9% | −7.3% |
| HDL (“good”) cholesterol | +5.2% | +1.4% |
| HbA1c, a blood sugar measure (5.7%) | −0.4 points | −0.2 points |
| Heart rate (72 beats a minute) | +3.5 beats a minute | −0.7 beats a minute |
The label says semaglutide lowers weight with more fat lost than lean mass. In STEP 1’s body-scan group, lean mass fell in kilograms, but its share of the body rose. Across STEP 1, people on semaglutide reported a bigger gain in physical functioning than on placebo, and nausea and diarrhea were the most common side effects, usually mild to moderate and passing. In the label’s pooled weight-loss trials, hair loss was reported by 3% on 2.4 mg (1% on placebo).
Why do online before-and-after photos vary so much? Results vary from person to person, and photos are chosen.
Same dose, different results
On 2.4 mg in STEP 1, 83.5% lost at least 5% by week 68, and 30.2% lost at least 20%. An average hides a wide range.
Different points in time
A month-3 photo and a month-16 photo show different stages: the dose steps take 16 weeks, and STEP 1 measured results at week 68.
Different health and doses
Type 2 diabetes, a 1.7 mg maintenance dose and stopping all changed results in the label’s trials: see why results can be slower.
Picked, not typical
The FTC warns that advertisers too often cherry-pick their most impressive cases, or even make up endorsements, and says an ad showing someone’s results must show typical results or clearly say what they are. It adds that misleading claims can come in images as well as words.
No photos here: trial numbers say more than one picture. Sources: the Wegovy prescribing information (revised June 2026) and the STEP 1 paper (2021). These trials studied FDA-approved Wegovy; compounded semaglutide wasn’t studied, and it isn’t FDA-approved. Your provider can tell you what your own progress means.
The schedule
What are semaglutide’s dose steps, week by week?
The Wegovy label (revised June 2026) starts at 0.25 mg a week, then steps up every 4 weeks: 0.5 mg, 1 mg and 1.7 mg. From week 17, the maintenance dose is 1.7 or 2.4 mg. It’s the label’s schedule; your prescription sets your doses and their timing.
Weeks 1 to 4: 0.25 mg
The label’s starting dose, once a week.
Weeks 5 to 8: 0.5 mg
Step two. The label steps up every 4 weeks to reduce stomach side effects.
Weeks 9 to 12: 1 mg
Step three. If a step isn’t tolerated, the label says to consider waiting 4 weeks before the next one.
Weeks 13 to 16: 1.7 mg
Step four, the last step before maintenance.
Week 17 on: 1.7 or 2.4 mg
Maintenance; the label recommends 2.4 mg. Its main trial measured results at week 68.
The label’s five dose steps, in order. Your prescriber’s instructions and the label come first.
The Wegovy injection schedule for adults, from its prescribing information (revised June 2026): the label’s schedule, not a personal plan. It steps up this way to reduce stomach side effects, and if a step isn’t tolerated, it says to consider waiting 4 weeks before the next one. More: compounded semaglutide side effects.
Higher than 2.4 mg? The label allows up to 7.2 mg (Wegovy HD) for adults who have taken 2.4 mg for at least 4 weeks and need more weight loss, as their prescriber decides.
On the daily Wegovy pill, the steps run by day: 1.5 mg for days 1 to 30, 4 mg for days 31 to 60, 9 mg for days 61 to 90, then 25 mg.
Missed 2 or more weekly doses in a row? The label says to restart the dose steps at a lower dose, to lower the risk of stomach side effects (read Nov. 15, 2026). Your provider sets the dose. More: restarting semaglutide after a break.
Compounded semaglutide follows your prescription, which may pace the steps differently. Our semaglutide dosage chart has the same mg steps and turns each dose into units for your vial.
“Product concentrations also may vary depending on the compounder, and a single compounder may offer multiple concentrations of compounded semaglutide products.”
U.S. Food and Drug Administration, FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (July 26, 2024)
Vial math
How many units is your semaglutide dose?
Your semaglutide dose in units depends on your vial’s strength. Here are the Wegovy label’s dose steps at two example strengths.
| Weeks | Weekly dose | At 2.5 mg/mL | At 5 mg/mL |
|---|---|---|---|
| 1 to 4 | 0.25 mg | 0.1 mL (10 units) | 0.05 mL (5 units) |
| 5 to 8 | 0.5 mg | 0.2 mL (20 units) | 0.1 mL (10 units) |
| 9 to 12 | 1 mg | 0.4 mL (40 units) | 0.2 mL (20 units) |
| 13 to 16 | 1.7 mg | 0.68 mL (68 units) | 0.34 mL (34 units) |
| 17 onward | 2.4 mg | 0.96 mL (96 units) | 0.48 mL (48 units) |
The math: mL = dose ÷ strength (mg per mL); units = mL × 100. At 2.5 mg/mL, 1 mg is 1 ÷ 2.5 = 0.4 mL, or 40 units. At 5 mg/mL, the same 1 mg is 0.2 mL, or 20 units.
Both strengths are examples only. The same dose is a different number of units at a different strength, so read the strength on your own vial’s label. Your prescription sets your dose and schedule, which may differ from these label steps. If your label’s units differ from this chart, follow the label and ask your pharmacy. Every step: the semaglutide dosage chart. Or enter your own vial’s strength in the semaglutide dosage calculator.
Results
What semaglutide results did the Wegovy trial show at 68 weeks?
In the label’s main trial, people on 2.4 mg lost 14.9% of their body weight on average, against 2.4% on placebo. About 8 in 10 (83.5%) lost at least 5%, and 30.2% lost at least 20%. The trial studied FDA-approved Wegovy; compounded semaglutide wasn’t studied. The shares tell you more than the average.
| Result at week 68 | Wegovy 2.4 mg | Placebo |
|---|---|---|
| Average weight change | −14.9% | −2.4% |
| Lost at least 5% | 83.5% | 31.1% |
| Lost at least 10% | 66.1% | 12% |
| Lost at least 15% | 47.9% | 4.8% |
| Lost at least 20% | 30.2% | 1.7% |
Swipe the table sideways to see every column.
Study 2 in the Wegovy label (the STEP 1 trial): 1,306 adults on 2.4 mg and 655 on placebo, without type 2 diabetes, all with a reduced-calorie diet and more physical activity. Wegovy prescribing information (revised June 2026), Table 8; the 20% row wasn’t among the trial’s pre-specified tests. These trials studied FDA-approved Wegovy; compounded semaglutide wasn’t studied.
Read the shares, not just the average. About 2 in 3 people on 2.4 mg lost at least 10%, and nearly half lost at least 15%. Some lost less than 5%: averages describe a group, not a person. Compounded semaglutide wasn’t studied.
On tirzepatide instead? Its own label results are in our tirzepatide results timeline.
HD and the pill
Do Wegovy HD and the Wegovy pill change the timeline?
A little. Wegovy HD (7.2 mg) adds one more step, for 20 weeks of dose steps, and averaged 18.8% at 72 weeks in its trial. The daily pill’s steps take 12 weeks, against the shot’s 16, and it averaged 13.6% at 64 weeks. These separate trials of FDA-approved Wegovy can’t be compared directly; compounded semaglutide wasn’t studied.
| Trial, in the Wegovy label | Length | Dose steps | Average weight loss, in the label | On placebo |
|---|---|---|---|---|
| Shot, 2.4 mgStudy 2 (STEP 1), Table 8 | 68 weeks | 16 weeks | 14.9% | 2.4% |
| Wegovy HD, 7.2 mgStudy 8 (STEP UP), Table 12 | 72 weeks | 20 weeks | 18.8% (15.5% on 2.4 mg in the same trial) | 3.9% |
| Pill, 25 mg a dayStudy 7, Table 11 | 64 weeks | 12 weeks | 13.6% | 2.4% |
Swipe the table sideways to see every column.
Average weight loss as the Wegovy prescribing information (revised June 2026) reports it, in Tables 8, 11 and 12; the dose steps are from its section 14.2. For Study 8, Novo Nordisk’s announcement of the first results (January 17, 2025) gave 18.7%, 15.6% and 3.9%, counting everyone whether or not they kept taking it; this page uses the label’s figures. Separate trials can’t be compared directly. These trials studied FDA-approved Wegovy; compounded semaglutide wasn’t studied.
Wegovy HD. In Study 8, the label reports, 63.8% of people on 7.2 mg lost at least 15%, versus 52.3% on 2.4 mg (a figure it gives for information only) and 7.5% on placebo. Across the two 7.2 mg trials, altered skin sensations, such as tingling or burning, were more common at 7.2 mg: 22%, versus 6% on 2.4 mg. Compounded semaglutide wasn’t studied.
The pill. In its trial, the dose steps took 12 weeks, against the shot’s 16. In that trial, Study 7 in the label, 47% of people on 25 mg lost at least 15%, versus 5.5% on placebo; compounded semaglutide wasn’t studied.
Compounded
Does compounded semaglutide follow the same timeline?
No one can say: compounded semaglutide wasn’t studied and isn’t FDA-approved. Your prescription may follow the label’s 4-week steps or pace them differently; the FDA’s GLP-1 page (updated October 1, 2026) lists reports of side effects that may be linked to doses above the label, or raised faster.
“Additionally, the agency has received adverse event reports that may be related to patients prescribed compounded semaglutide or tirzepatide products in doses beyond what is in the FDA-approved drug label.”
U.S. Food and Drug Administration, FDA’s Concerns with UnapprovedGLP-1 Drugs Used for Weight Loss
No trial data
Compounded semaglutide isn’t FDA-approved, and no trial has measured its results. The FDA doesn’t review compounded drugs for safety, effectiveness or quality before they’re sold.
Your prescription sets the steps
Your provider may follow the label’s 4-week steps or pace them differently for you. The FDA has reports of side effects that may be linked to compounded doses above the label, or raised faster.
Strength and units
Compounded vials come in different strengths, the FDA notes, so the same number of units can be a different dose. Check the mg/mL on every new label.
“Compounded drugs are not FDA-approved. This means the agency does not review their safety, effectiveness or quality before they are marketed.”
U.S. Food and Drug Administration, Understanding the Risks of Compounded Drugs
Unsure about a dose? Our semaglutide dosage chart converts any dose to units, for any vial strength.
Slower results
Why might your semaglutide results be slower?
Results can be slower while you’re still in the dose steps, with type 2 diabetes or on the lower 1.7 mg maintenance dose. In the Wegovy label’s trials, people with type 2 diabetes lost 9.6% on average at 68 weeks, less than in the main trial. Missed doses and breaks can slow things too. These trials studied FDA-approved Wegovy; compounded semaglutide wasn’t studied.
You’re still stepping up
On the label’s schedule, you’re below the maintenance dose for the first 16 weeks, and longer if a step is held.
Type 2 diabetes
In Study 3 in the label, adults with type 2 diabetes lost 9.6% on average at 68 weeks, versus 3.4% on placebo: less than in Study 2. Compounded semaglutide wasn’t studied.
Your maintenance dose
The label’s maintenance dose is 1.7 or 2.4 mg. In its Study 6, in East Asian adults, 1.7 mg averaged 9.6% and 2.4 mg 13.2% at 68 weeks, versus 2.1% on placebo; compounded semaglutide wasn’t studied.
Diet and activity
Every trial paired Wegovy with a reduced-calorie diet and more activity. In the label’s Study 4, with an intensive program that began with an 8-week low-calorie diet, people on 2.4 mg lost 16% on average, versus 5.7% on placebo. Compounded semaglutide wasn’t studied.
Stopping, or long breaks
In the label’s Study 5, people switched to placebo after 20 weeks saw their weight rise 6.9% by week 68, while those who stayed on 2.4 mg lost another 7.9% (compounded semaglutide wasn’t studied). Missed doses can also send you back down the steps.
Sleep, stress and the rest
A 2025 advisory from four obesity and nutrition groups lists activity, sleep, stress and social connection among the habits that support long-term success.
Trial figures from the Wegovy prescribing information (revised June 2026): Studies 3 and 4 from Table 8, Study 5 from Table 9 and Study 6 from Table 10. These trials studied FDA-approved Wegovy; compounded semaglutide wasn’t studied. More on eating: what to eat on a
At NexLife
How does NexLife follow your progress on semaglutide?
No one can promise a result. Here’s what care looks like at NexLife, from the first dose step on.
A licensed provider decides each step
Your provider looks at how you’re doing and decides when, or whether, to step up. Your dose follows how you respond, never the price.
Questions any time
Call or text
(949) 818-8000 . Real people answer 24/7, and physicians answer medical questions during clinical hours.Food and habits
Every plan includes a nutrition plan and a 1:1 coaching call.
One price, every step
$95 a month on the 12-month plan, $99 on 6 months, $105 on 3 months or $109 month to month. Each step up costs the same, with no membership fee. Compounded semaglutide isn’t FDA-approved or a generic Wegovy, and a licensed provider prescribes it only when it offers a significant difference for you.
Loved by our members
Real stories from NexLife members about their care and service.
A selection of 5-star reviews from Trustpilot, quoted in full as written. Results vary from person to person, and weight loss isn’t guaranteed.
★★★★★TrustScore 4.8 out of 5 on Trustpilot407 reviews as of Nov. 15, 2026 · Read them all ↗
★★★★★Read on Trustpilot ↗
“Great communication. Easy to work with. They work to set you up for success.”
Anthony C.
★★★★★Read on Trustpilot ↗
“Fast delivery and easy to get a hold of when needing to talk with someone!”
Browneyes
★★★★★Read on Trustpilot ↗
“So happy with NexLife. Communication has been great, I’m recommending them to all my friends.”
April
★★★★★Read on Trustpilot ↗
“Excellent visit. Dr. Kennah was very knowledgeable and helpful and answered all my questions.”
Ethan B.
★★★★★Read on Trustpilot ↗
“That’s a real site with good prices and plans!”
Estefany L.
★★★★★Read on Trustpilot ↗
“Affordable, quick and easy. They could not have made it a smoother less stressful experience.”
Andisheh K.
★★★★★Read on Trustpilot ↗
“Great communciation and was fast and reliable”
Kiki
★★★★★Read on Trustpilot ↗
“Very happy so far”
Tammy E.
★★★★★Read on Trustpilot ↗
“Fast service great communication!! Willing to work with you!”
Bon
★★★★★Read on Trustpilot ↗
“Great service and excellent communication!”
Gabrielle D.
★★★★★Read on Trustpilot ↗
“Easy and pricing not bad! Customer service was helpful in answering my questions.”
Lyndy T.
★★★★★Read on Trustpilot ↗
“Good experience, great team”
Mai S.
Names are shortened for privacy. Reviews are members’ opinions, not medical advice.
What does NexLife cost?
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†
GIP + 12-month plan $115/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan, $1,380 paid upfront; $129/mo month to month, billed monthly.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication

12-month plan $95/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
TrustScore 4.8 out of 5 on Trustpilot 407 reviews as of Nov. 15, 2026 · Read them all ↗
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms
The NexLife Price Match Guarantee†
Paying less elsewhere?
Keep your price. Upgrade your care.
Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.
- 1Send a receipt from the last 60 days
- 2A NexLife provider reviews your prescription
- 3Pay your matched price, at every dose
Locked while your plan is activeSame price at every doseNo membership fee
†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.
Semaglutide results: your questions
Fair questions about NexLife
- Will my price go up with my dose?
- No. You pay the same at every dose.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
How long does it take to see results on semaglutide?
Weight comes off over months, not weeks. The Wegovy label steps the dose up every 4 weeks and reaches maintenance in week 17, and its main trial measured results at week 68 (compounded semaglutide wasn’t studied). Your provider can tell you what your own progress means.
What do semaglutide before and after results look like?
In STEP 1 (Study 2 in the Wegovy label), a 68-week trial, people on 2.4 mg started at 105.4 kg on average and lost 14.9% of their weight, versus 2.4% on placebo, and their waists shrank 13.5 cm on average (4.1 cm on placebo). These are trial averages for FDA-approved Wegovy, not a promise: results varied, and compounded semaglutide wasn’t studied.
How much weight can you lose on semaglutide in 3 months?
The Wegovy label gives no 3-month result: those weeks are dose steps, and its main trials report results at week 68. The nearest is Study 5. People who reached 2.4 mg during a 20-week lead-in went from 107.2 kg to 96.1 kg on average, a group the label says may not reflect everyone. Compounded semaglutide wasn’t studied.
What did people lose on Wegovy after 68 weeks?
In Wegovy’s 68-week trial, people on 2.4 mg lost 14.9% of their body weight on average, versus 2.4% on placebo (label, June 2026). In that trial, 47.9% lost at least 15% of their weight, versus 4.8% on placebo. It studied FDA-approved Wegovy; compounded semaglutide wasn’t studied.
Is the timeline different on compounded semaglutide?
No one can say: compounded semaglutide isn’t FDA-approved, and no trial has measured its timeline. The FDA doesn’t review compounded drugs for safety, effectiveness or quality before they’re sold. Your prescription may follow the label’s 4-week steps or pace them differently. For how compounded and brand-name versions differ, see compounded semaglutide vs. Wegovy.
How long does the Wegovy pill take to work?
Its dose steps take 12 weeks, against the shot’s 16, by the Wegovy label (revised June 2026). In its 64-week trial, the 25 mg pill averaged 13.6% weight loss, versus 2.4% on placebo; it studied FDA-approved Wegovy, not compounded semaglutide. The pill and the shot weren’t compared head to head: see [GLP-1 pills vs. injections](/pages/glp-1-pills-vs-injections).
Does Wegovy HD lead to more weight loss?
In its 72-week trial, yes: the label reports 18.8% average weight loss on 7.2 mg, versus 15.5% on 2.4 mg and 3.9% on placebo. The label allows 7.2 mg only after at least 4 weeks on 2.4 mg, when more weight loss is needed. That trial studied FDA-approved Wegovy; compounded semaglutide wasn’t studied.
Does tirzepatide work better than semaglutide?
In separate trials, as each label reports, Zepbound 15 mg averaged 20.9% weight loss at 72 weeks and Wegovy 2.4 mg 14.9% at 68 weeks, but separate trials can’t be compared directly. Compounded versions of either weren’t studied. Our tirzepatide vs. semaglutide guide covers the trial that compared them head to head.
What happens if I stop taking semaglutide?
Weight tends to come back. In a Wegovy trial in the label, people switched to placebo after 20 weeks saw their weight rise 6.9% by week 68, while those who stayed on it lost another 7.9% (compounded semaglutide wasn’t studied). Talk with your provider before you stop.
Why am I losing weight slowly on semaglutide?
You may still be stepping up: the label’s maintenance dose starts in week 17. In Wegovy’s main trial, 83.5% on 2.4 mg lost at least 5%, so not everyone did. In another trial, people with type 2 diabetes lost less: 9.6% on average at 68 weeks. Compounded semaglutide wasn’t studied; your provider can review your dose and habits.
What happens in the first month on semaglutide?
On the Wegovy label, weeks 1 to 4 are the starting dose of 0.25 mg once a week. The label steps up every 4 weeks to reduce stomach side effects. In your first weeks, you’re still on starting doses; the main trial measured results at week 68. Compounded semaglutide wasn’t studied.
Do you need diet and exercise with semaglutide?
The trials included both: every Wegovy trial paired the medicine with a reduced-calorie diet and more activity. In the label’s Study 4, which began with an 8-week low-calorie diet, people on 2.4 mg lost 16% on average, versus 5.7% on placebo. Compounded semaglutide wasn’t studied.
Does 2.4 mg semaglutide work better than 1.7 mg?
On average, yes: in the Wegovy label’s Study 6, in East Asian adults, 2.4 mg averaged 13.2% weight loss at 68 weeks and 1.7 mg 9.6%, versus 2.1% on placebo. The label recommends 2.4 mg for maintenance, and your provider decides whether to step up. Compounded semaglutide wasn’t studied.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC), or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2). The most common side effects include nausea, diarrhea, vomiting, constipation and stomach pain.
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. The FDA warned on Nov. 9, 2026, that GLP-1 medicines may raise the risk of NAION, a rare eye condition that can cause sudden vision loss in one eye; call your provider right away if that happens (FDA). Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed 503A partner pharmacies, Absolute Pharmacy (Lutz, FL) and Boudreaux’s New Drug Store (Lake Charles, LA), fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
Who wrote and medically reviewed this page?
Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.
Checked every number against the Wegovy and Zepbound labels on November 1, 2026.
- How we checked. The dose schedule, the trial results and the pill and Wegovy HD figures come from the Wegovy prescribing information (revised June 2026), which we read on November 15, 2026. Where Novo Nordisk’s January 17, 2025 announcement of the STEP UP trial gives slightly different Wegovy HD figures, we use the label’s and name both. The Zepbound figure comes from its label (revised August 2026), and the vial guidance from the FDA, both read the same day. Trial numbers are averages from trials of FDA-approved Wegovy; compounded semaglutide wasn’t studied. We don’t give a dosing plan: your provider decides.
- Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email hello@nexlife.us and we’ll fix it.
- How we work. How we review programs · GLP-1 price index · Is NexLife legit? · States NexLife serves
Paying less elsewhere? We match it.†
You know the timeline. Next: a 3-minute check.
A licensed provider reviews your health history and decides if compounded semaglutide is right for you. $95 a month on the 12-month plan, or $109 month to month, at every dose.
4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026) · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
- 1Tell us about you
Start online with your health history.
- 2A licensed provider decides
Online, following your state’s rules. You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.
Sources
- Wegovy (semaglutide) prescribing information, Novo Nordisk (revised June 2026). Read November 15, 2026.
- Wegovy prescribing information, the FDA’s copy of the same June 2026 revision. Read November 15, 2026; section 2.4 (missed doses) read Nov. 15, 2026.
- Novo Nordisk: semaglutide 7.2 mg in the STEP UP obesity trial, first results (January 17, 2025). Read November 1, 2026.
- ClinicalTrials.gov: STEP UP (NCT05646706), Study 8 in the Wegovy label. Checked October 25, 2026.
- Zepbound (tirzepatide) prescribing information, Eli Lilly (revised August 2026). Read November 15, 2026.
- FDA: concerns with unapproved
GLP-1 drugs used for weight loss (content current as of October 1, 2026). Read November 15, 2026. - FDA: dosing errors associated with compounded injectable semaglutide products (July 26, 2024). Read November 15, 2026.
- Mozaffarian D, et al. Nutritional priorities to support
GLP-1 therapy for obesity: a joint advisory. Obesity, 2025;33(8):1475-1503. Read November 15, 2026. - NexLife: compounded semaglutide dosage chart.
- NexLife: pricing, every plan. Checked November 15, 2026.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Content current as of September 16, 2025; read November 15, 2026.
- U.S. Food and Drug Administration. Understanding the Risks of Compounded Drugs. Content current as of June 22, 2026; read November 15, 2026.
- Eli Lilly and Company, on Drugs@FDA. Zepbound (tirzepatide) prescribing information, revised February 2026 (FDA’s copy). Read November 15, 2026.
- U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Content current as of October 30, 2026; read November 15, 2026.
- The New England Journal of Medicine. Once-weekly semaglutide in adults with overweight or obesity (STEP 1), 2021. Read November 18, 2026.
- Federal Trade Commission. Gut Check: A Reference Guide for Media on Spotting False Weight Loss Claims (2014; last modified July 16, 2020). Read November 18, 2026.